AMAG seeks broader iron deficiency anemia use for Feraheme
This article was originally published in Scrip
Executive Summary
The markets had little reaction to AMAG Pharmaceuticals' 24 December revelation it had submitted a supplemental new drug application (sNDA) to the US FDA for broader iron deficiency anemia (IDA) use of Feraheme (ferumoxytol) beyond the currently approved chronic kidney disease (CKD) adult population, with shares of the firm only nudging up 1.3%, or 7 cents, before closing down 2 cents at $15.13.